| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $777,067 | 5 | 63 |
Sells | $5,513,926 | 3 | 37 |
| BIENAIME JEAN JACQUES | director | 3 | $699,337 | 0 | $0 | $699,337 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer | 2 | $77,730 | 0 | $0 | $77,730 |
| HOLTUG LARS | director | 0 | $0 | 1 | $62,335 | $-62,335 |
| Bodenhoff Mads | SVP & PAO | 0 | $0 | 1 | $810,570 | $-810,570 |
| JENSEN FLEMMING STEEN | See Remarks | 0 | $0 | 1 | $4.64M | $-4.64M |
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development …
Over the last 12 months, insiders at Ascendis Pharma A/S have bought $777,067 and sold $5.51M worth of Ascendis Pharma A/S stock.
On average, over the past 5 years, insiders at Ascendis Pharma A/S have bought $777,067 and sold $5.51M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BIENAIME JEAN JACQUES (director) — $699,337. SMITH SCOTT THOMAS (EVP & Chief Financial Officer) — $77,730.
The last purchase of 2,000 shares for transaction amount of $492,654 was made by BIENAIME JEAN JACQUES (director) on 2026‑08‑14.
| 2026-09-08 | Sale | Bodenhoff Mads | SVP & PAO | 3,000 0.0047% | $270.19 | $810,570 | -12.80% | |
| 2026-09-02 | Sale | HOLTUG LARS | director | 236 0.0004% | $264.13 | $62,335 | -11.13% | |
| 2026-08-14 | BIENAIME JEAN JACQUES | director | 2,000 0.0031% | $246.33 | $492,654 | -1.71% | ||
| 2026-06-02 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | 100 0.0002% | $219.00 | $21,900 | +14.73% | ||
| 2026-05-29 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | 250 0.0004% | $223.32 | $55,830 | +10.62% | ||
| 2026-05-29 | BIENAIME JEAN JACQUES | director | 500 0.0008% | $223.12 | $111,562 | +10.62% | ||
| 2026-05-26 | BIENAIME JEAN JACQUES | director | 400 0.0007% | $237.80 | $95,121 | +3.29% | ||
| 2026-05-11 | Sale | JENSEN FLEMMING STEEN | See Remarks | 19,460 0.0315% | $238.49 | $4.64M | +2.93% |
| Increased Positions | 184 | +63.67% | 6M | +10.08% |
| Decreased Positions | 130 | -44.98% | 6M | -8.86% |
| New Positions | 64 | New | 2M | New |
| Sold Out Positions | 37 | Sold Out | 888,809 | Sold Out |
| Total Postitions | 343 | +18.69% | 65M | +1.22% |